Skip to main content
OpenTrials
Completed

NCT Number: NCT04176302

Monitoring of Mobility of Parkinson's Patients for Therapeutic Purposes - Clinical Trial

When Parkinson Disease is mild, it responds well to treatment with drugs (L-Dopa and dopamine antagonists). However, as the disease progresses, the effect of the drugs diminishes and lasts for a shorter time (wearing-off), which require physicians to progressively increase and/or break up the dosage of dopamine drugs, to control symptoms over the course of the entire day. Despite this, most patients present motor fluctuations after 10 years. These fluctuations consist of changes between what are known as Off periods, when the medication does not produce an effect and mobility is hindered, and On periods when patients can move smoothly, with the medication producing its best effect.

The timeline of these motor fluctuations over the course of the day and also on different days is very valuable to precisely adjust the medication. Nevertheless, neurologists do not currently have detailed information on the timeline of the symptoms of their patients, which means that they have serious difficulties to obtain good results with the adjustment of medication. Currently, the neurologist's information on the time progression of the motor fluctuations is drawn from what the patient indicates in the office visit, or in the best case, from diaries that the patient fills out at home, periodically (e.g. every hour) noting the motor state (On or Off). Although the latter method is still the gold standard in research and in care, it has serious limitations, because patients often forget to record the information (especially when they are in Off), many do not recognize their motor states well, and few can maintain adherence to such a laborious system for more than a few days.

The Parkinson Holter (STAT-ON ®) is a wearable device, which objectively measures and records the motor fluctuations of the patients. It does not require intervention by the patient, and can, therefore, be used in daily life, long term if necessary. However, the concept that detailed knowledge of motor fluctuations of patients will lead to better control of the disease, thanks to optimisation of the therapeutic regimen, is still a hypothesis. To demonstrate or refute this hypothesis, we are now conducting a clinical trial, with this medical device, to study the clinical effectiveness in patients with moderate Parkinson's disease and motor fluctuations. This trial will show whether using the Parkinson Holter is better than the clinical interview used in traditional clinical practice (primary objective), and whether it is not inferior to the On-Off diary recorded by the patients at home (exploratory objective)

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Hospital Universitari Vall d'Hebron, Barcelona, Spain

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Ideopathic Parkinson's Disease
  • Disease in the moderate-severe phase (Hoehn & Yahr ≥ 2 en Off)
  • Motor fluctuations (with at least 2h/day in Off)
  • Agree to participate voluntarily and will sign a written consent form

Exclusion criteria

  • Incapable of walking independently or H&Y=5
  • Participating in another clinical trial
  • Patients with acute intercurrent disease
  • Psychiatric or cognitive disorders that prevent collaboration (MMSE <24)

Treatment and study plan

Parkinson Holter

Device

The neurologists will receive the wearable report (for medication adjustment, if any as per physician's criteria/judgement)

Other names: STAT-ON ® sensor

Motor fluctuations diary

Diagnostic Test

The neurologists will receive the patient's diary report (for medication adjustment, if any as per physician's criteria/judgement).

Other names: Parkinson's diary

Traditional clinical practice

Other

The neurologists will receive the patient & caregiver report at the time of the visit (for medication adjustment, if any as per physician's criteria/judgement).

Other names: Clinical interview

Primary outcomes

  1. Daily time in Off

    Time frame: 7 days

    Changes from baseline to last visit in daily hours in Off

Secondary outcomes

  1. Number of clinical contacts

    Time frame: 6 months

    Number of patient visits and telephone controls to adjust medication

  2. Patient's adherence to the MF measurement system

    Time frame: 7 days

    Total hour/days with information registered.

  3. Number of therapeutic changes.

    Time frame: 6 months

    Number of therapeutic changes done to improve symptoms.

  4. Motor complications

    Time frame: 6 months

    Changes from baseline to last visit in motor complications, assessed by means of Unified Parkinson's Disease Rating Scale - part IV

  5. Daily time in On

    Time frame: 7 days

    Changes from baseline to last visit in daily hours in On

  6. Change of presence and severity of freezing of gait episodes

    Time frame: 7 days

    Changes from baseline to last visit in the number and severity of freezing of gait episodes, assessed by means of Freezing of Gait Questionnaire

  7. Reported quality of life

    Time frame: 1 month

    Changes from baseline to last visit in quality of life, assessed by menas of Parkinson's Disease Questionnaire-39

  8. Activities of Daily Living

    Time frame: 6 months

    Changes from baseline to last visit in dependence for Activities of Daily Living assessed by means of Unified Parkinson's Disease Rating Scale - part II

  9. User satisfaction: Quebec User Evaluation of Satisfaction with assistive Technology

    Time frame: 7 days

    Physician and patient satisfaction with the Parkinson Holter will be assessed by means of the Quebec User Evaluation of Satisfaction with assistive Technology (QUEST)

  10. System usability: System Usability Scale

    Time frame: 7 days

    Usability of the system will be assessed by System Usability Scale (SUS)

Sponsors and collaborators

Lead sponsor

Consorci Sanitari de l'Alt Penedès i Garraf

Other

Collaborators

  • European Regional Development Fund
  • Instituto de Salud Carlos III

Registry information

Acronym: MoMoPa-EC

Important dates

Study start
2019
Primary completion
2022
Study completion
2023
First posted
Nov 25, 2019
Registry last updated
Dec 5, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.